Intranet_FF9900-transparent
Login
Linkedin
Twitter
Envelope
  • About EUnetHTA
    • History of EUnetHTA
      • JA 3 (2016-2020)
      • JA 2 Archive (2012-2015)
      • JA 1 Archive (2010-2012)
      • EUnetHTA Collaboration (2009)
      • EUnetHTA Project (2006-2008)
    • EUnetHTA Network
    • Organisation
      • The Executive Board
      • The Secretariat
    • Vision, Mission, and Values
    • EUnetHTA and the HTA Network
    • EUnetHTA Magazine
      • Winter 2020
      • Autumn 2019
      • Summer 2019
      • Winter 2018-2019
      • Autumn 2018
      • Summer 2018
      • Spring 2018
      • Winter 2017 – 2018
      • Autumn 2017
    • Acronyms
  • Covid-19 Response
    • Diagnostics
    • Treatments
    • Useful Links
  • Services
    • Assessment Submission
    • Early Dialogues
      • Early Dialogues for Pharmaceutical Products
      • Early Dialogues for Medical Devices
    • PLEG
  • Assessments
    • EUnetHTA Prioritisation List (EPL) – Pharmaceuticals
    • EUnetHTA Prioritisation List (EPL) – Other Technologies
    • Assessments REA (2016 – 2021)
    • Topic Identification, Selection and Prioritisation
    • National Uptake and Case Studies
    • PICO FAQ
    • Assessment Archive (2006 – 2015)
    • Assessment FAQ
  • Tools
    • HTA Core Model®
    • Methodology
    • REQueST® Tool
    • POP Database
    • EVIDENT Database
    • Declaration of Interest (DOI)
    • Submission Template for Pharma and Med. Devices
    • Companion Guide
    • Tools Archive
      • HTA Adaptation Toolkit
  • Get Involved
    • Patients
    • Industry
    • Health Care Professionals
    • Payers
    • Regulators
    • Events
      • 2021 EUnetHTA Forum
      • 2020 EUnetHTA Forum
      • 2019 EUnetHTA Forum
      • 2018 EUnetHTA Forum
      • 2017 EUnetHTA Forum
      • Upcoming Events
Menu
  • About EUnetHTA
    • History of EUnetHTA
      • JA 3 (2016-2020)
      • JA 2 Archive (2012-2015)
      • JA 1 Archive (2010-2012)
      • EUnetHTA Collaboration (2009)
      • EUnetHTA Project (2006-2008)
    • EUnetHTA Network
    • Organisation
      • The Executive Board
      • The Secretariat
    • Vision, Mission, and Values
    • EUnetHTA and the HTA Network
    • EUnetHTA Magazine
      • Winter 2020
      • Autumn 2019
      • Summer 2019
      • Winter 2018-2019
      • Autumn 2018
      • Summer 2018
      • Spring 2018
      • Winter 2017 – 2018
      • Autumn 2017
    • Acronyms
  • Covid-19 Response
    • Diagnostics
    • Treatments
    • Useful Links
  • Services
    • Assessment Submission
    • Early Dialogues
      • Early Dialogues for Pharmaceutical Products
      • Early Dialogues for Medical Devices
    • PLEG
  • Assessments
    • EUnetHTA Prioritisation List (EPL) – Pharmaceuticals
    • EUnetHTA Prioritisation List (EPL) – Other Technologies
    • Assessments REA (2016 – 2021)
    • Topic Identification, Selection and Prioritisation
    • National Uptake and Case Studies
    • PICO FAQ
    • Assessment Archive (2006 – 2015)
    • Assessment FAQ
  • Tools
    • HTA Core Model®
    • Methodology
    • REQueST® Tool
    • POP Database
    • EVIDENT Database
    • Declaration of Interest (DOI)
    • Submission Template for Pharma and Med. Devices
    • Companion Guide
    • Tools Archive
      • HTA Adaptation Toolkit
  • Get Involved
    • Patients
    • Industry
    • Health Care Professionals
    • Payers
    • Regulators
    • Events
      • 2021 EUnetHTA Forum
      • 2020 EUnetHTA Forum
      • 2019 EUnetHTA Forum
      • 2018 EUnetHTA Forum
      • 2017 EUnetHTA Forum
      • Upcoming Events

AVALIA-T

Home
AVALIA-T

Galician Agency for HTA

Edificio administrativo San Lázaro s/n,

Santiago de Compostela

Spain

Tel.: +34 881 541 831

Fax: +34 881 542 854

Email: avalia-t@sergas.es

http://avalia-t.sergas.es

EUnetHTA involvement

As Associated Partner

  • EUnetHTA Project (2006-08)
    • Project WP4 – Common Core HTA
    • Project WP6 – HTA and Health Policy
    • Project WP7 – New Technologies
    • Project WP8 – System to support HTA
  • EUnetHTA Joint Action 3 (2016-20)
    • Work Package 7 – National implementation and impact
    • Work Package 4 – Joint Production
    • Work Package 5 – Life cycle approach to improve Evidence Generation

As Collaborating partner

  • EUnetHTA Joint Action 2 (2012-15)
    • JA2 WP2 – Dissemination
    • JA2 WP4 – Testing collaborative production of HTA information for national adaptation and reporting
    • JA2 WP5 – Applying the HTA Core Model for Rapid Assessment for national adaptation and reporting
    • JA2 WP7 – Methodology development and evidence generation: Guidelines and pilots production
  • EUnetHTA Joint Action (2010-12)
    • JA WP4 – Core HTA
    • JA WP7 – New Technologies

OUR NETWORK

  • EUnetHTA Network
  • JA 3 (2016-2021)
  • JA 2 Archive (2012-2015)
  • JA 1 Archive (2010-2012)
  • EUnetHTA Collaboration (2009)
  • EUnetHTA Project (2006-2008)
Menu
  • EUnetHTA Network
  • JA 3 (2016-2021)
  • JA 2 Archive (2012-2015)
  • JA 1 Archive (2010-2012)
  • EUnetHTA Collaboration (2009)
  • EUnetHTA Project (2006-2008)

CAREERS

  • Work with EUnetHTA
Menu
  • Work with EUnetHTA

HELP

eunethta@zinl.nl

CONTACT US

  • Media and Press
  • Disclaimer
  • Reusing our content
  • Terms of use
  • Privacy Policy
Menu
  • Media and Press
  • Disclaimer
  • Reusing our content
  • Terms of use
  • Privacy Policy

This website is part of joint action ‘724130 / EUnetHTA JA3’ which has received funding from the European Union’s Health Programme (2014-2020).

©2021 EUnetHTA All rights reserved.

This website uses cookies to ensure you get the best experience on our website. By using the website you agree to our Privacy Policy and our Terms of Use.
Accept and Close